Amgen files brief to Supreme Court ahead of oral arguments — with industry amicus support

Amgen is coming out swinging against Sanofi and Regeneron in a Supreme Court case with substantial implications.

In its brief filed Dec. 27, the Big Pharma laid out its case, saying among other things that the Federal Circuit’s standard harms innovation and alters the “basic patent bargain” — denying an inventor a patent based sheerly on the number of possible embodiments, even if the patent’s disclosures teach the world how to “make and use” the claimed invention.